Depiction of Prostate Cancer Treatment Alternatives in Greece

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00733213
First received: August 8, 2008
Last updated: October 13, 2009
Last verified: October 2009
  Purpose

A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice.

  • Target Group: Patients with locally advanced or metastatic prostate cancer.
  • The first 10 consecutive patients records that meet the entry criteria.

Condition
Locally Advanced or Metastatic Prostate Cancer.

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Depiction of Prostate Cancer Treatment Alternatives in Greece

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Percentage of patients treated by each treatment alternative. [ Time Frame: Between 2002 - 2008 ]

Secondary Outcome Measures:
  • To depict sociodemographic characteristics and comorbidities. [ Time Frame: Between 2002 - 2008 ]

Estimated Enrollment: 310
Study Start Date: January 2008
Study Completion Date: March 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer

Criteria

Inclusion Criteria:

  • Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002.
  • Patients that received Hormonal therapy.

Exclusion Criteria:

  • Males that are aged less than 18 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00733213

Locations
Greece
Research Site
Athens, Greece
Research Site
Karditsa, Greece
Research Site
Serres, Greece
Research Site
Xsanthi, Greece
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Panagiotis Pontikis, MD AstraZeneca Greece
  More Information

No publications provided

Responsible Party: Dr Pontikis Panagiotis, MD Medical and Regulatory Affairs Director, AstraZeneca, SA Greece
ClinicalTrials.gov Identifier: NCT00733213     History of Changes
Other Study ID Numbers: NIS-OGR-DUM-2007/1
Study First Received: August 8, 2008
Last Updated: October 13, 2009
Health Authority: Greece: National Organization of Medicines

Keywords provided by AstraZeneca:
Prostate Cancer, Treatment alternatives, Metastasis

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on October 30, 2014